Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.67% $1.480
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 4.78 mill |
EPS: | -3.33 |
P/E: | -0.440 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 3.23 mill |
Avg Daily Volume: | 0.0179 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.440 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.07x |
Company: PE -0.440 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.41 (62.78%) $0.929 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 1.385 - 1.575 ( +/- 6.42%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Favorito Tamara A | Buy | 2 000 | Stock Option (right to buy) |
2024-02-28 | Favorito Tamara A | Buy | 1 083 | Stock Option (right to buy) |
2024-02-28 | Favorito Tamara A | Buy | 667 | Stock Option (right to buy) |
2024-02-28 | Favorito Tamara A | Sell | 1 083 | Stock Option (right to buy) |
2024-02-28 | Favorito Tamara A | Sell | 2 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
16.62 |
Last 100 transactions |
Buy: 2 033 762 | Sell: 346 866 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.480 (-0.67% ) |
Volume | 0.0160 mill |
Avg. Vol. | 0.0179 mill |
% of Avg. Vol | 89.31 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.